Compare WIMI & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIMI | GNTA |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | China | Italy |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 34.0M |
| IPO Year | 2019 | N/A |
| Metric | WIMI | GNTA |
|---|---|---|
| Price | $1.90 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.1K | ★ 53.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.71 |
| 52 Week High | $7.26 | $10.00 |
| Indicator | WIMI | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 39.45 |
| Support Level | N/A | $0.71 |
| Resistance Level | $3.06 | $1.70 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 44.76 | 17.75 |
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.